Post-ASCO 25: Pamela Tenaerts on CGTs and digital-first long-term follow-up

When it comes to CGTs, long-term follow-up care is an issue that makes patient access to these novel investigative treatments extremely limited, given the 15 years that patients must still engage with the trial after receiving the medication. In a post-ASCO 2025 conversation, pharmaphorum web editor Nicole Raleigh spoke with Dr Pamela Tenaerts, chief medical officer at Medable, about the company’s new digital-first model to handle long-term follow-up care for cell and gene therapy cancer trials. Tenaerts explains how the company’s approach prioritises patient comfort, simplifies trial execution, and enhances patient engagement, and is designed specifically for sponsors, CROs, clinical ops leaders, and healthcare providers You can also listen to episode 193a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.